Clinical Trial Detail

NCT ID NCT02139358
Title Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

Her2-receptor positive breast cancer

Therapies

Gemcitabine + Pertuzumab + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST